Schonfeld Strategic Advisors LLC Increases Stock Position in GSK plc (NYSE:GSK)

Schonfeld Strategic Advisors LLC increased its position in shares of GSK plc (NYSE:GSK) by 68.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,237,034 shares of the pharmaceutical company’s stock after buying an additional 907,068 shares during the period. GSK comprises approximately 0.4% of Schonfeld Strategic Advisors LLC’s holdings, making the stock its 18th biggest holding. Schonfeld Strategic Advisors LLC’s holdings in GSK were worth $75,656,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC increased its stake in GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after buying an additional 278 shares during the period. GC Wealth Management RIA LLC increased its stake in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after buying an additional 353 shares during the period. Jacobi Capital Management LLC increased its stake in GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after buying an additional 389 shares during the period. Gladstone Institutional Advisory LLC increased its stake in GSK by 3.4% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock worth $413,000 after buying an additional 407 shares during the period. Finally, CENTRAL TRUST Co increased its stake in GSK by 5.6% during the 4th quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock worth $262,000 after buying an additional 414 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective for the company. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 24th. Eight investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, GSK currently has an average rating of “Moderate Buy” and an average target price of $40.58.

GSK Trading Up 1.8 %

GSK stock opened at $38.09 on Tuesday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a 50-day moving average price of $37.53 and a two-hundred day moving average price of $35.99. The firm has a market capitalization of $78.59 billion, a price-to-earnings ratio of 23.96, a PEG ratio of 1.12 and a beta of 0.56. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 10th. Shareholders of record on Friday, February 21st were given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.13%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. GSK’s payout ratio is 100.63%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.